Bulk Pharmaceutical API Sources for VYTORIN

Bulk Pharmaceutical API Sources for VYTORIN

Vendor	Vendor Homepage	Vendor Sku	API Url
BenchChem		B1244729
THE BioTek		bt-1577684
RR Scientific		R6267342

Bulk Active Pharmaceutical Ingredient (API) Sources for VYTORIN

Last updated: February 19, 2026

This report details the bulk Active Pharmaceutical Ingredient (API) sources for VYTORIN (ezetimibe/simvastatin), a combination drug used to lower cholesterol. Key information includes the primary API components, their manufacturers, and the patent landscape affecting API supply.

What are the Active Pharmaceutical Ingredients in VYTORIN?

VYTORIN is a fixed-dose combination product containing two distinct APIs:

• Ezetimibe: A cholesterol absorption inhibitor.
• Simvastatin: A statin, which reduces the liver's production of cholesterol.

These two APIs are co-formulated into a single tablet.

Who Manufactures the APIs for VYTORIN?

The manufacturing of bulk APIs for branded and generic versions of VYTORIN involves multiple suppliers, often influenced by patent expiry and licensing agreements.

Ezetimibe API Manufacturers

Original innovator-grade ezetimibe API was primarily produced by Merck & Co., Inc. (known as MSD outside the U.S. and Canada). Following patent expiries, numerous contract manufacturing organizations (CMOs) and generic API producers have entered the market. Key global regions for ezetimibe API production include India, China, and some European countries. Specific manufacturers are dynamic and depend on current market demand, regulatory approvals (e.g., U.S. FDA, EMA), and commercial partnerships. Companies known to have produced or to currently produce ezetimibe API for generic formulations include:

• Dr. Reddy's Laboratories: A major Indian pharmaceutical company with significant API manufacturing capabilities.
• Sun Pharmaceutical Industries Ltd.: Another large Indian pharmaceutical firm with a broad API portfolio.
• Lupin Ltd.: An Indian multinational pharmaceutical company that manufactures APIs.
• Cipla Ltd.: A significant player in the Indian pharmaceutical sector, involved in API production.
• Zhejiang NHU Co., Ltd.: A Chinese chemical and pharmaceutical company.

Simvastatin API Manufacturers

Simvastatin API has been produced by a wide array of manufacturers globally for decades, given its long history and widespread use. Similar to ezetimibe, production is concentrated in India and China, with some European manufacturers also active. The original innovator for simvastatin was Merck & Co., Inc. (as Zocor). Generic simvastatin API suppliers include:

• Aurobindo Pharma Limited: An Indian vertically integrated pharmaceutical company.
• Divi's Laboratories: A prominent Indian API and intermediates manufacturer.
• Teva Pharmaceutical Industries Ltd.: A global pharmaceutical company with extensive API production.
• Piramal Pharma Solutions: A contract development and manufacturing organization (CDMO) that produces APIs.
• Novartis AG (through Sandoz division): A global healthcare company with a strong generics arm.

It is crucial to note that specific suppliers for any given pharmaceutical formulation are often proprietary information, determined by contracts between the finished dosage form manufacturer and the API supplier. Regulatory filings with agencies like the U.S. Food and Drug Administration (FDA) list approved API sources through Drug Master Files (DMFs).

What is the Patent Landscape for VYTORIN and its APIs?

The patent landscape significantly influences the availability and cost of bulk APIs for VYTORIN, particularly for the ezetimibe component, which has a more complex patent history than simvastatin.

Ezetimibe Patents

The primary patents protecting ezetimibe have expired in major markets, allowing for generic competition. Merck's original patents on ezetimibe were fundamental composition of matter patents.

• U.S. Patent No. 5,766,597: This patent, covering ezetimibe, expired in 2017. This was a critical patent for Merck's ezetimibe franchise.
• European Patents: Similar composition of matter patents expired across Europe around the same timeframe.

While composition of matter patents have expired, secondary patents relating to specific crystalline forms (polymorphs), manufacturing processes, or formulations might still exist or have expired more recently. Generic manufacturers must navigate this landscape to ensure freedom to operate. The expiry of the key patents allowed for the widespread introduction of generic ezetimibe and, consequently, generic VYTORIN.

Simvastatin Patents

Simvastatin has been off-patent for a considerable period. The original patents for simvastatin expired much earlier, typically in the early to mid-2000s in most major markets, paving the way for widespread generic availability of both simvastatin alone and in combination products.

Combination Product Patents

Patents related to the fixed-dose combination of ezetimibe and simvastatin (i.e., VYTORIN itself) also played a role. Merck held patents covering the combination formulation, dosage regimen, and methods of use. The expiry of these combination patents further facilitated generic market entry. For instance, key patents on the combination product itself have expired, allowing generic manufacturers to market their own versions.

API Sourcing Considerations for VYTORIN

For pharmaceutical companies seeking to source bulk APIs for VYTORIN, several factors are critical:

Regulatory Compliance

• U.S. FDA and EMA Approval: API manufacturers must have their facilities inspected and approved by regulatory bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).
• Drug Master Files (DMFs): API suppliers typically maintain DMFs with regulatory agencies. These confidential documents provide detailed information about the manufacturing process, quality control, and specifications of the API. The finished drug product manufacturer references these DMFs in their own drug application (e.g., ANDA in the U.S.).
• Good Manufacturing Practices (GMP): All API manufacturing must adhere to stringent GMP guidelines to ensure consistent quality, purity, and safety.

Quality and Purity

• Impurity Profiles: Generic manufacturers must ensure that APIs sourced from different suppliers meet the same stringent impurity profiles as the innovator product and comply with regulatory limits.
• Physical Properties: Consistent physical characteristics of the API (e.g., particle size distribution, polymorphic form) are crucial for tablet formulation and dissolution.

Supply Chain Reliability

• Dual Sourcing: To mitigate supply chain risks, companies often pursue dual or multi-sourcing strategies for critical APIs like ezetimibe and simvastatin.
• Geopolitical Stability: Reliance on APIs from specific regions necessitates an assessment of geopolitical risks, trade policies, and potential disruptions.

Cost-Effectiveness

• Competitive Bidding: The generic API market is highly competitive. Companies engage in competitive bidding processes to secure the most cost-effective API supply.
• Long-Term Contracts: Establishing long-term supply agreements can provide price stability and guaranteed volumes.

Key Takeaways

• VYTORIN contains two APIs: ezetimibe and simvastatin.
• Original innovator API production was by Merck & Co., Inc.
• Generic ezetimibe API is manufactured by companies primarily in India and China, following patent expiries around 2017.
• Generic simvastatin API production is widespread, with original patents having expired much earlier.
• Regulatory compliance, including GMP and DMF submission, is paramount for API suppliers.
• Supply chain reliability, quality control, and cost-effectiveness are key considerations for API sourcing.

Frequently Asked Questions

1. What is the typical lead time for sourcing bulk ezetimibe API? Lead times can vary significantly depending on the manufacturer's current production schedule, order volume, and existing supply agreements. Generally, it can range from 3 to 9 months from order placement to delivery for large volumes, assuming the manufacturer has available capacity.

2. Are there specific GMP certifications required for VYTORIN API suppliers? Yes, suppliers must comply with current Good Manufacturing Practices (cGMP) as defined by regulatory bodies such as the U.S. FDA, EMA, and WHO. Specific certifications like ISO 9001 are often held, but FDA/EMA cGMP compliance is non-negotiable for market access.

3. How do regulatory filings (DMFs) impact API sourcing decisions? Drug Master Files (DMFs) are essential. Finished dosage form manufacturers must ensure that the API supplier's DMF is active and accepted by the relevant regulatory agency for inclusion in their drug application (e.g., ANDA). The quality and completeness of the DMF influence the speed of regulatory review.

4. What are the primary risks associated with relying on a single API supplier for VYTORIN? Risks include supply chain disruptions due to manufacturing issues, natural disasters, geopolitical events, or supplier-specific problems (e.g., regulatory actions against the facility). This can lead to drug shortages and significant financial losses.

5. Can patent litigation impact the availability of VYTORIN APIs? Yes, patent litigation can impact API availability. While primary patents for ezetimibe and simvastatin have expired, litigation can arise over secondary patents (e.g., process patents, polymorph patents). Such disputes can temporarily halt production or sales by certain manufacturers if injunctions are granted.

Citations

[1] U.S. Food & Drug Administration. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. Retrieved from https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-approved-drug-products-therapeutic-equivalence-evaluations [2] European Medicines Agency. (n.d.). European Public Assessment Reports (EPARs). Retrieved from https://www.ema.europa.eu/en/medicines/human/EPARs (Note: Specific EPARs for VYTORIN and its components would be referenced here if available and directly cited for patent expiration details). [3] Publicly available patent databases (e.g., Google Patents, USPTO Patent Database) were consulted for U.S. Patent No. 5,766,597 and related ezetimibe patents.